Ahsan Usmani, MD
Interventional Pain Medicine · Richmond, INNPI 1336133289
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $310 of the $410 with a category attached, or 75.6%. 10 manufacturers reported payments, led by Johnson & Johnson at 24.4% of the total. That places this record below the midpoint for interventional pain medicine clinicians in IN, where the typical reported total is $4,157.
Across 12 payments — averaging $34.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$100
- Boston Scientific$90
- Akcea Therapeutics, Inc.$72
- Medtronic$32
- Viiv Healthcare Company$30
- Merck$23
- plus $64 from 4 others
What the payments were for
- Food & beverage$31076%
- Education$10024%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 1 | $100 |
| Boston Scientific | 2 | $90 |
| Akcea Therapeutics, Inc. | 1 | $72 |
| Medtronic | 2 | $32 |
| Viiv Healthcare Company | 1 | $30 |
| Merck | 1 | $23 |
| GRT US Holding, Inc. | 1 | $18 |
| Si-bone, Inc. | 1 | $18 |
| Tolmar, Inc. | 1 | $17 |
| Pacira Therapeutics, Inc. | 1 | $11 |
How this compares
$410 in reported general payments places this provider in the 10th percentile of 68 interventional pain medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gabapentin | 669 | $5,812 |
| Lidocaine | 21 | $2,599 |
| Pregabalin | 71 | $1,255 |
| Duloxetine Hcl | 94 | $770 |
| Methocarbamol | 128 | $703 |
| Tizanidine Hcl | 81 | $559 |
| Amitriptyline Hcl | 72 | $523 |
| Cyclobenzaprine Hcl | 31 | $469 |
| Baclofen | 81 | $467 |
| Topiramate | 82 | $176 |
| Methylprednisolone | 22 | $135 |
Paid to pharmacies, not to this prescriber.
Other interventional pain medicine in Richmond
- Joshua WellingtonCarmel$315K
- Joseph RutledgeLafayette$96K
- Orlando LandrumElkhart$34K
- Mahendra SanapatiEvansville$31K
- Nikhil ShettyMunster$29K
- David GordonIndianapolis$28K
- Vinayak BelamkarIndianapolis$28K
- Jocelyn BushIndianapolis$20K
- Scott KimGreenwood$18K
- Edward KowlowitzIndianapolis$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.